At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 160 enrolled
Drug / intervention
Nateglinide 120 mg +1 moredrug
Likely dose
Nateglinide 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients
In Brief
A Phase 4 clinical trial evaluating Nateglinide 120 mg and Acarbose 50 mg for Diabetes Mellitus, Type 2. Completed, enrolled 160 participants across 6 sites.
Detailed Summary
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartJul 2009
Primary CompletionJun 2010
TodayJul 2026
First PostedJun 26, 2009
Enrollment StartJul 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.0 years ago
Interventions
Nateglinide 120 mgdrug
Nateglinide 120 mg was supplied as tablets.
Acarbose 50 mgdrug
Acarbose 50 mg was supplied as tablets.